Mankind Pharma reported Q4FY26 PAT growth of 31.7% YoY to ₹554 crore, while revenue increased 11.8% to ₹3,443 crore. FY26 revenue rose 17% to ₹14,278 crore, though annual PAT declined 3.6% to ₹1,938 crore. The company also completed acquisition of Bharat Serums and Vaccines for ₹13,768 crore during FY26.